What is Nilogen Oncosystems?
Nilogen Oncosystems operates at the intersection of advanced biotechnology and precision medicine, specializing in the development of innovative 3D cancer models. Utilizing its patented 3D-EXplore technology, the company effectively captures tumor heterogeneity directly from fresh human tumor tissue. This unique approach allows for a high-fidelity representation of the tumor microenvironment, which is critical for modern drug development. The firm provides comprehensive services that support biomarker discovery, the advancement of cell therapies, and the refinement of immuno-oncology treatments. By offering deep insights into therapeutic responses, Nilogen Oncosystems enables pharmaceutical partners to make data-driven decisions, ultimately increasing the probability of success in complex clinical trials and therapeutic pipelines.
How much funding has Nilogen Oncosystems raised?
Nilogen Oncosystems has raised a total of $92K across 1 funding round:
Debt
$92K
Debt (2021): $92K with participation from PPP
Key Investors in Nilogen Oncosystems
PPP
Public-Private Partnership
What's next for Nilogen Oncosystems?
With the recent infusion of capital, Nilogen Oncosystems is poised to transition into a more aggressive growth phase, focusing on the expansion of its laboratory infrastructure and the broadening of its bioinformatics support services. The company is expected to prioritize the scaling of its 3D-EXplore platform to meet the rising demand for human-centric tumor models in drug discovery. Strategic objectives likely include the strengthening of partnerships with global pharmaceutical entities and the further validation of its analytical models in late-stage clinical settings. As the oncology market continues to shift toward personalized medicine, Nilogen Oncosystems remains a critical enabler for developers seeking to navigate the complexities of tumor biology and improve patient outcomes through superior preclinical intelligence.
See full Nilogen Oncosystems company page
